Helen M. Thackray, Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 14,000 shares at $8.29 ($116K) on 2023-04-03, disclosed to the SEC on 2023-04-05.
Scheduled sale ($116k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.29 | 7,000 | $58K | 50.0% |
| 2 | $8.29 | 7,000 | $58K | 50.0% |
| Total | $8.29 avg | 14,000 | $116K | 100% |
| Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |
| GLYC | SELL | 2017-09-18 | $26K | — | Filing → |